SCHEDULE 13G/A: Catalys Pacific Maintains 13.5% Stake in Mineralys Therapeutics
Beneficial Ownership Disclosure
Catalys Pacific and its affiliates reported continued beneficial ownership of 13.5% of Mineralys Therapeutics, Inc.'s common stock as of June 30, 2025.
Summary
- Catalys Pacific Fund, LP, Catalys Pacific Fund GP, LP, Catalys Pacific, LLC, and Brian Taylor Slingsby collectively reported beneficial ownership of 8,978,954 shares of Mineralys Therapeutics, Inc. common stock.
- This ownership represents 13.5% of the company's outstanding common stock.
- The beneficial ownership includes 8,903,838 shares held of record by Catalys Pacific Fund, LP and 75,116 shares underlying stock options exercisable within 60 days of June 30, 2025.
- The percentage is based on 66,295,184 shares of common stock outstanding as of August 7, 2025, as disclosed in Mineralys Therapeutics' Quarterly Report on Form 10-Q filed on August 12, 2025.
- This document is an Amendment No. 2 to a previous Schedule 13G filing.
Sentiment
Score: 5
Explanation: The filing is a routine disclosure of beneficial ownership by a significant investor group, providing factual information without indicating positive or negative operational or financial performance.
Positives
- NA
Negatives
- NA
Risks
- NA
Future Outlook
NA
Industry Context
This filing indicates continued institutional investment in a biotechnology company. Without more context on Mineralys Therapeutics' specific pipeline or market position, a detailed industry analysis is not possible from this document alone.
Stakeholder Impact
- Shareholders: Provides transparency regarding a significant institutional holding, which can influence market perception.
- Management: Awareness of a large, stable shareholder base.
Key Dates
| Date | Description |
|---|---|
| 06/30/2025 | Date of event which requires filing of this statement (ownership snapshot date). |
| 08/07/2025 | Date as of which 66,295,184 shares of Common Stock were outstanding, as disclosed in the Issuer's Form 10-Q. |
| 08/12/2025 | Date the Issuer's Quarterly Report on Form 10-Q was filed with the SEC. |
| 08/14/2025 | Date of signing of this Schedule 13G Amendment No. 2. |
Recommendation
holdThis Schedule 13G filing is a routine disclosure of a significant, stable beneficial ownership stake by Catalys Pacific. It does not contain new financial or operational information about Mineralys Therapeutics that would warrant a change in investment thesis. Investors should 'hold' and await further operational or financial updates from the company to make a more informed decision.
Keywords
Mineralys Therapeutics, Catalys Pacific, beneficial ownership, Schedule 13G, common stock, institutional investor, biotech, pharmaceutical
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.